APEX1 and neoplasm: Further, the results of Western blot and ELISA demonstrated that the Erlotinib treatment led to increased levels of APE1, IL‐6 and p‐STAT3/STAT3 in tumour tissues, which could further be increased in response to HCC827R‐CSC‐EVs (all p < .01).